The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Multidisciplinary approaches to managing stage II-III operable lung cancer
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses key insights from a multidisciplinary session at BTOG 2025 on managing stage 2-3 operable lung cancer. Experts debated the role of preoperative chemoimmunotherapy, particularly for PD-L1 negative patients, and the selection of patients for surgery versus neoadjuvant strategies. Emphasizing the importance of achieving an R0 resection, Prof. Popat highlights the need for true multidisciplinary collaboration in patient selection. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
